Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Annals of Surgical Oncology
|
October 18, 2024
Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis
Kailan Sierra-Davidson, Aikaterini Dedeilia, Aleigha Lawless, et al.
Annals of Surgical Oncology
|
December 9, 2024
ASO Visual Abstract: Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparepvec-A Single-Institution Retrospective Analysis
Kailan Sierra-Davidson, Aikaterini Dedeilia, Aleigha Lawless, et al.
Annals of Surgical Oncology
|
December 29, 2023
Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma
Aikaterini Dedeilia, Thinzar Lwin, Siming Li, et al.
The Oncologist
|
June 24, 2025
Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma
Amélie Ciernik, Laure Ciernik, Peter Bonczkowitz, et al.
Cancer Medicine
|
December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations
Derek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Molecular Therapy. Oncology
|
March 4, 2025
Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade
Ana Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, et al.
JCO Precision Oncology
|
January 18, 2024
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma
Takuto Sato, Kamaneh Montazeri, Evangelos S Gragoudas, et al.
Annals of Surgical Oncology
|
June 5, 2026
ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response
Aleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Annals of Surgical Oncology
|
May 23, 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response
Aleigha Lawless, Derek N Effiom, Alma Burbano, et al.
JAMA Network Open
|
August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma
Rachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Annals of Surgical Oncology
|
October 18, 2024
Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis
Kailan Sierra-Davidson, Aikaterini Dedeilia, Aleigha Lawless, et al.
Annals of Surgical Oncology
|
December 9, 2024
ASO Visual Abstract: Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparepvec-A Single-Institution Retrospective Analysis
Kailan Sierra-Davidson, Aikaterini Dedeilia, Aleigha Lawless, et al.
Annals of Surgical Oncology
|
December 29, 2023
Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma
Aikaterini Dedeilia, Thinzar Lwin, Siming Li, et al.
The Oncologist
|
June 24, 2025
Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma
Amélie Ciernik, Laure Ciernik, Peter Bonczkowitz, et al.
Cancer Medicine
|
December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations
Derek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Molecular Therapy. Oncology
|
March 4, 2025
Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade
Ana Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, et al.
JCO Precision Oncology
|
January 18, 2024
Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma
Takuto Sato, Kamaneh Montazeri, Evangelos S Gragoudas, et al.
Annals of Surgical Oncology
|
June 5, 2026
ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response
Aleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Annals of Surgical Oncology
|
May 23, 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response
Aleigha Lawless, Derek N Effiom, Alma Burbano, et al.
JAMA Network Open
|
August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma
Rachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
Page
of 3